Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3766942 | 1.00 | SLC5A2 (0.62) | SLC5A2SLC5A1 | |
| SCHEMBL12588984 | 0.99 | SLC5A2 (0.61) | SLC5A2SLC5A1 | |
| SCHEMBL14182084 | 0.91 | SLC5A2 (0.58) | SLC5A2SLC5A1 | |
| SCHEMBL12646355 | 0.89 | SLC5A2 (0.49) | SLC5A2SLC5A1 | |
| SCHEMBL3772852 | 0.87 | SLC5A2 (0.50) | SLC5A2SLC5A1 | |
| SCHEMBL797556 | 0.87 | SLC5A2 (0.50) | SLC5A2SLC5A1 | |
| SCHEMBL3775262 | 0.87 | SLC5A2 (0.56) | SLC5A2SLC5A1 | |
| SCHEMBL797496 | 0.86 | SLC5A2 (0.49) | SLC5A2SLC5A1 | |
| SCHEMBL3775903 | 0.84 | SLC5A2 (0.66) | SLC5A2SLC5A1 | |
| SCHEMBL2044669 | 0.83 | SLC5A2 (0.65) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883743-B2 | Methods for treating obesity employing an SGLT2 inhibitor | ASTRAZENECA AB (SE) | 2014-11-11 | — | — | US | disclosed |
| US-8883743-B2 | Methods for treating obesity employing an SGLT2 inhibitor | ASTRAZENECA AB (SE) | 2014-11-11 | — | — | US | disclosed |
| US-20120077739-A1 | METHODS FOR TREATING OBESITY EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITIONS THEREOF | BRISTOL-MYERS SQUIBB (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077739-A1 | METHODS FOR TREATING OBESITY EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITIONS THEREOF | BRISTOL-MYERS SQUIBB (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120071403-A1 | Methods for Treating Type 2 Diabetes in Patients Resistant to Previous Treatment with other Anti-Diabetic Drugs Employing an SGLT2 Inhibitor and Compositions Thereof | ASTRAZENECA UK LIMITED (GB) | 2012-03-22 | — | — | US | disclosed |
| US-20120071403-A1 | Methods for Treating Type 2 Diabetes in Patients Resistant to Previous Treatment with other Anti-Diabetic Drugs Employing an SGLT2 Inhibitor and Compositions Thereof | ASTRAZENECA UK LIMITED (GB) | 2012-03-22 | — | — | US | disclosed |
| US-7956041-B2 | antidiabetic mixture contains an inhibitor of renal glucose reabsorption and a hypoglycemic agent; controlling blood glucose level; tolbutamide, chlorpropamide, glibenclamide, glipizide, glimepiride, and gliclazide; metformin, phenformin and buformin; repaglinide, nateglinide and mitiglinide | AJINOMOTO CO., INC. (JP) | 2011-06-07 | — | — | US | disclosed |
| US-7956041-B2 | antidiabetic mixture contains an inhibitor of renal glucose reabsorption and a hypoglycemic agent; controlling blood glucose level; tolbutamide, chlorpropamide, glibenclamide, glipizide, glimepiride, and gliclazide; metformin, phenformin and buformin; repaglinide, nateglinide and mitiglinide | AJINOMOTO CO., INC. (JP) | 2011-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077739-A1 | METHODS FOR TREATING OBESITY EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITIONS THEREOF | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885 |
| US-20120071403-A1 | Methods for Treating Type 2 Diabetes in Patients Resistant to Previous Treatment with other Anti-Diabetic Drugs Employing an SGLT2 Inhibitor and Compositions Thereof | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.